- Home
- CTNM vs EU Comparison
CTNM vs EU Comparison
Compare CTNM & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNM | EU |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Other Metals and Minerals |
| Sector | | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 575.3M | 464.5M |
| IPO Year | 2024 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CTNM | EU |
|---|---|---|
| Price | $13.77 | $1.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $18.60 | $4.00 |
| AVG Volume (30 Days) | 188.4K | ★ 3.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $58,334,000.00 |
| Revenue This Year | N/A | $17.41 |
| Revenue Next Year | N/A | $95.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.38 |
| 52 Week Low | $3.35 | $1.01 |
| 52 Week High | $16.33 | $4.19 |
Technical Indicators
Market Signals| Indicator | CTNM | EU |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 27.58 |
| Support Level | $10.17 | N/A |
| Resistance Level | $16.17 | $2.83 |
| Average True Range (ATR) | 0.99 | 0.19 |
| MACD | -0.32 | -0.08 |
| Stochastic Oscillator | 17.57 | 1.61 |
Price Performance
Historical ComparisonAbout CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.